Compare TransMedics Group Inc (TMDX) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? TransMedics Group Inc trades at $87.76 (market cap $3.10B), while Vanguard Dividend Appreciation Index Fund ETF trades at $246.21. The key difference: Vanguard Dividend Appreciation Index Fund ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| TMDX | VIG | |
|---|---|---|
Market Cap | $3.10B | — |
Sector | Technology | — |
52-Week High | $150.42 | $245.79 |
52-Week Low | $61.99 | $208.67 |
Enterprise Value | $3.49B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
VIG trades at $245.92, up 0.05% on the day, with a bullish technical bias from moving averages but overbought RSI signals. The ETF focuses on dividend growth stocks like Broadcom, offering a 1.5% yield with a 20-year dividend growth streak. Recent news highlights its role in retirement income strategies amid Social Security adjustments.
Outlook remains positive for long-term investors seeking stable dividend growth, though high RSI levels suggest near-term consolidation risks. Competition with higher-yield ETFs and market volatility pose challenges, but institutional interest and consistent methodology support resilience.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
